Division of Vascular and Endovascular Surgery, Duke University Medical Center, Durham, NC.
Division of Vascular and Endovascular Surgery, General Hospital & Paracelsus Medical University Nuremberg, Nuremberg, Germany.
Ann Vasc Surg. 2024 Sep;106:247-254. doi: 10.1016/j.avsg.2024.03.016. Epub 2024 May 28.
The early postoperative benefits of endovascular aneurysm repair (EVAR) have been well established but questions remain regarding its durability at mid-term and long-term time points. Long-term results in real-world use of EVAR outside of randomized trial data are limited. This study used the Global Registry for Endovascular Aortic Treatment registry to explore the 5-year outcomes with the GORE EXCLUDER device in real-world clinical circumstances.
All patients within the Global Registry for Endovascular Aortic Treatment registry who underwent an infrarenal abdominal aortic aneurysm repair with the GORE EXCLUDER device were included in this study. Baseline characteristics and demographic information of the cohort were collected. End points included mortality (all-cause and aneurysm-related), serious endoleaks, aneurysm sac diameter, endograft integrity (fracture, compression, migration), post-EVAR aortic rupture, device-related reintervention, conversion to open repair, graft explantation, and major adverse cardiovascular events.
A total of 3,216 patients were included in this analysis. The cohort reflected a significantly comorbid population with 46% of patients reaching a Charlson Comorbidity Index score of ≥5. Follow-up at 5 years was 60% of eligible participants. The freedom from aortic-related mortality was at 98.8% and overall survival was 71.2%. Postoperative major adverse cardiovascular events occurred in 49 (1.5%) patients. Device-related intervention through 5 years was 7.2% and the overall serious endoleak rate was 6.8%. Less than 1% of patients required an open conversion/revision and aortic rupture following device placement occurred in 15 (0.5%) patients. Aneurysm sac regression was achieved in 58.1% of patients at 5 years, and stability/absence of growth was observed in 83.6% at 5 years.
This study supports the durability of the GORE EXCLUDER device through 5 years with negligible incidence of graft integrity compromise and low aortic/device-related reintervention rates. Furthermore, the efficacy of the device is highlighted with low aortic-related mortality and high sac regression/stability diameter through 5 years.
血管内动脉瘤修复术(EVAR)的早期术后获益已得到充分证实,但对于其在中期和长期时间点的耐久性仍存在疑问。在随机试验数据之外,真实世界中 EVAR 的长期结果有限。本研究使用全球血管内主动脉治疗登记处(Global Registry for Endovascular Aortic Treatment registry)探讨了真实世界临床情况下 Gore Excluder 装置的 5 年结果。
本研究纳入了全球血管内主动脉治疗登记处(Global Registry for Endovascular Aortic Treatment registry)中所有接受 Gore Excluder 装置治疗的腹主动脉瘤患者。收集了队列的基线特征和人口统计学信息。终点包括死亡率(全因和动脉瘤相关)、严重内漏、动脉瘤囊直径、移植物完整性(骨折、压缩、迁移)、EVAR 后主动脉破裂、与器械相关的再次干预、转为开放修复、移植物取出和主要不良心血管事件。
共纳入 3216 例患者。该队列反映了一个显著合并症患者群体,其中 46%的患者Charlson 合并症指数评分≥5。5 年随访率为符合条件患者的 60%。主动脉相关死亡率的无事件生存率为 98.8%,总生存率为 71.2%。术后发生重大不良心血管事件 49 例(1.5%)。5 年内与器械相关的干预为 7.2%,总体严重内漏率为 6.8%。不到 1%的患者需要开放转换/修正,放置器械后发生主动脉破裂 15 例(0.5%)。5 年后,58.1%的患者达到动脉瘤囊缩小,5 年后 83.6%的患者稳定/无瘤体增大。
本研究支持 Gore Excluder 装置在 5 年内的耐久性,移植物完整性受损发生率低,主动脉/器械相关再干预率低。此外,该装置的疗效显著,5 年内主动脉相关死亡率低,瘤囊缩小/稳定直径高。